-- Launched the UniCel DxC 880i, an integrated workcell that consolidates
chemistry and immunoassay testing for high-volume laboratories. This
latest addition to the company's workcell family combines Beckman
Coulter's market-leading chemistry system, the UniCel DxC 800, and the
industry's highest-throughput immunoassay system, the UniCel DxI 800.
-- Named Scott Garrett, president and chief executive officer, to the
additional post of chairman of the board, effective April 24, 2008.
-- Named Betty Woods, the company's previous non-executive chairman, as
lead independent director, effective April 24, 2008.
-- Announced that the company's Board of Directors authorized the
repurchase of up to 2.5 million shares of the company's outstanding
-- Declared a $0.17 per share quarterly cash dividend payable on
May 23, 2008 to all stockholders of record on May 9, 2008. This payout
represents the 76th consecutive, quarterly payout of dividends.
-- Entered into an agreement with Siemens Healthcare Diagnostics for
sublicenses of certain rights relating to testing for the hepatitis C
virus (HCV). Under the agreement, Beckman Coulter can develop,
manufacture and sell a quantitative viral load HCV blood test for use
on the company's molecular diagnostic instrument, which is in
Full Year Outlook
|SOURCE Beckman Coulter, Inc.|
Copyright©2008 PR Newswire.
All rights reserved